You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Macular Degeneration, Wet

Showing 1 - 25 of 3,798
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Macular Degeneration, Wet, Metamorphopsia Trial

Recruiting
  • Macular Degeneration, Wet
  • Metamorphopsia
    • Cuneo, Piedmont, Italy
      Ospedale Santa Croce
    Sep 20, 2022

    Age-related Wet Macular Degeneration Trial in United States (CG-P5 peptide, Placebo, Aflibercept Injection [Eylea])

    Not yet recruiting
    • Age-related Wet Macular Degeneration
    • CG-P5 peptide
    • +2 more
    • Augusta, Georgia
    • +3 more
    Nov 13, 2023

    Intestinal Microbiome in Wet Age-related Macular Degeneration

    Recruiting
    • Age-Related Macular Degeneration
    • Sample examination
    • Ioánnina, Epirus, Greece
    • +1 more
    Feb 23, 2023

    Age-Related Macular Degeneration Trial in Toronto (NG101 AAV gene therapy)

    Not yet recruiting
    • Age-Related Macular Degeneration
    • NG101 AAV gene therapy
    • Toronto, Ontario, Canada
      Vitreous Retina Macula Specialists of Toronto
    Aug 2, 2023

    Data of Intravitreal Aflibercept Injection in Patients of Wet

    Completed
    • Wet Age-related Macular Degeneration
    • Aflibercept (Eylea, BAY86-5321)
    • Multiple Locations, India
      Many Locations
    Feb 2, 2023

    Wet Age-related Macular Degeneration Trial in Beijing (RC28-E, Aflibercept)

    Recruiting
    • Wet Age-related Macular Degeneration
    • Beijing, Beijing, China
      Beijing Hospital
    Feb 3, 2023

    Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD) Trial (aflibercept 8 mg PFS)

    Not yet recruiting
    • Diabetic Macular Edema (DME)
    • Neovascular Age-Related Macular Degeneration (nAMD)
    • aflibercept 8 mg PFS
    • (no location specified)
    Aug 3, 2023

    Artificial Intelligence Diagnostic Aid

    Not yet recruiting
    • Wet Macular Degeneration
    • +2 more
    • Macusense Assessment Software
    • London, Westminster, United Kingdom
      Guy's and St Thomas's NHS Foundation Trust
    Dec 29, 2022

    Neovascular Age-related Macular Degeneration Trial (FT-003)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • FT-003
    • (no location specified)
    Nov 21, 2022

    OCT Angiography in Wet AMD

    Recruiting
    • Neovascular (Wet) Age-related Macular Degeneration (AMD)
    • Optical Coherence Tomography
    • Portland, Oregon
      Casey Eye Institute, Oregon Health & Science University
    Sep 20, 2022

    Single Injection of Faricimab for nAMD With Persisting Fluid

    Active, not recruiting
    • Neovascular Age-related Macular Degeneration
    • Glostrup, Denmark
      Miklos Schneider
    Nov 3, 2023

    Neovascular Age-related Macular Degeneration Trial in Graz (Aflibercept 40 MG/ML, Faricimab 120 MG/ML)

    Recruiting
    • Neovascular Age-related Macular Degeneration
    • Aflibercept 40 MG/ML
    • Faricimab 120 MG/ML
    • Graz, Styria, Austria
      Department of Ophthalmolgy, Medical University Graz
    Jul 3, 2023

    Neovascular Age-related Macular Degeneration Trial (RRG001)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • (no location specified)
    Nov 15, 2023

    Neovascular (Wet) Age-related Macular Degeneration (nAMD) Trial (EXG102-031)

    Not yet recruiting
    • Neovascular (Wet) Age-related Macular Degeneration (nAMD)
    • EXG102-031
    • (no location specified)
    Jun 13, 2023

    Optical Coherence Tomography Angiography Criteria Of The

    Not yet recruiting
    • Choroidal Neovascular Membrane In Wet Age Related Macular Degeneration And In Pathological Myopia
    • Optical coherence tomography angiography
    • (no location specified)
    Sep 27, 2022

    Neovascular Age-related Macular Degeneration Trial in Phoenix (CLS-AX, Aflibercept)

    Recruiting
    • Neovascular Age-related Macular Degeneration
    • Phoenix, Arizona
      Retinal Research Institute, LLC
    Jun 4, 2023

    Neovascular Age-related Macular Degeneration Trial in Suzhou (Aflibercept Ophthalmic, IBI302)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • Aflibercept Ophthalmic
    • IBI302
    • Suzhou, Jiangsu, China
      Innovent Biologics (Suzhou) Co,Ltd.
    Jul 25, 2023

    Neovascular Age-related Macular Degeneration Trial (PMC-403)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • (no location specified)
    Jul 11, 2023

    Neovascular Age-related Macular Degeneration Trial (AXT107 Low Dose, AXT107 Mid Dose, AXT107 High Dose)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • AXT107 Low Dose
    • +2 more
    • (no location specified)
    May 5, 2023

    Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in Beijing (Intravitreal injection of IBI302(dose 1),

    Suspended
    • Neovascular Age-related Macular Degeneration
    • Diabetic Macular Edema
    • Intravitreal injection of IBI302(dose 1)
    • +3 more
    • Beijing, Beijing, China
      Peking University People's Hospital
    Jul 17, 2023

    s in Wet Age-related Macular Degeneration Which Have Never

    Active, not recruiting
    • Wet Age-related Macular Degeneration
    • Aflibercept (Eylea, BAY86-5321)
    • Multiple Locations, Argentina
    • +16 more
    Jan 16, 2023

    Wet Age-related Macular Degeneration Trial in Beijing, Wuhan, Shanghai (CMAB818, Lucentis®)

    Recruiting
    • Wet Age-related Macular Degeneration
    • Beijing, Beijing, China
    • +3 more
    Jun 14, 2022

    Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in Austin (AIV007)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • Diabetic Macular Edema
    • Austin, Texas
      Retina Consultants of Austin
    Jan 16, 2023

    Neovascular Age-related Macular Degeneration (nAMD) Trial in Abilene (OCU-10-C-110 for Injection)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration (nAMD)
    • OCU-10-C-110 for Injection
    • Abilene, Texas
      Retina Research Institute of Texas
    Jun 6, 2023

    Neovascular Age-related Macular Degeneration (nAMD) Trial (AR-14034 SR implant lower dose, Aflibercept Injection, Sham

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration (nAMD)
    • AR-14034 SR implant lower dose
    • +3 more
    • (no location specified)
    Mar 3, 2023